Sidorkiewicz Stéphanie, Tran Viet-Thi, Cousyn Cécile, Perrodeau Elodie, Ravaud Philippe
Department of General Medicine, Paris Descartes University, Paris, France METHODS Team, Epidemiology and Statistics Sorbonne Paris Cité Research Centre, UMR 1153, INSERM, Paris, France.
METHODS Team, Epidemiology and Statistics Sorbonne Paris Cité Research Centre, UMR 1153, INSERM, Paris, France Department of General Medicine, Paris Diderot University, Paris, France.
BMJ Open. 2016 May 10;6(5):e010510. doi: 10.1136/bmjopen-2015-010510.
To develop and validate an instrument to assess adherence to each individual drug taken by patients undergoing long-term treatment.
Multicentre prospective observational validation study.
Six general practitioners' clinics and 6 university hospitals in Paris, France.
Patients 18 years and older receiving at least one long-term treatment.
The instrument was developed from a literature search and interviews with experts. Clarity and wording were assessed during pilot testing with 51 patients. The tool was validated in a sample of consecutive patients. We assessed agreement between adherence measured with our tool and drug diaries and compared measurements from our instrument with (1) the Lu instrument; (2) the Adherence Estimator (AE); (3) patient's adherence assessed by physicians; (4) the Morisky Medication Adherence Scale-4 items (MMAS-4); and (5) the Treatment Burden Questionnaire (TBQ). Reliability was assessed by a test-retest method.
A total of 243 patients taking 961 drugs were recruited in 2014. We found good agreement between adherence measured by our tool and drug diaries (intraclass correlation coefficient (ICC) 0.69, 95% CI 0.34 to 0.91) and a linear relationship between measurement with our tool and (1) the Lu instrument (p<0.01); (2) 2 items of the AE (perceived need for medication (p<0.01) and concerns about medication (p<0.01)); (3) patients' adherence assessed by their physicians (p<0.01); (4) the MMAS-4 (p<0.01) and (5) the TBQ (p<0.01). Reliability of the retest was good (ICC 0.67, 95% CI 0.42 to 0.85).
We developed an instrument with acceptable validity and reliability to assess adherence for each drug taken by patients, usable in hospital and primary care settings.
开发并验证一种工具,以评估接受长期治疗的患者对所服用的每种药物的依从性。
多中心前瞻性观察性验证研究。
法国巴黎的6家全科医生诊所和6家大学医院。
18岁及以上接受至少一种长期治疗的患者。
该工具是通过文献检索和专家访谈开发的。在对51名患者进行预试验期间评估了清晰度和措辞。该工具在连续患者样本中得到验证。我们评估了用我们的工具测量的依从性与药物日记之间的一致性,并将我们工具的测量结果与(1)卢氏工具;(2)依从性估计器(AE);(3)医生评估的患者依从性;(4)4项版的莫利斯基药物依从性量表(MMAS - 4);以及(5)治疗负担问卷(TBQ)进行比较。通过重测法评估可靠性。
2014年共招募了243名服用961种药物的患者。我们发现我们的工具测量的依从性与药物日记之间具有良好的一致性(组内相关系数(ICC)为0.69,95%置信区间为0.34至0.91),并且我们的工具测量结果与(1)卢氏工具(p<0.01);(2)AE的2项(对药物的感知需求(p<0.01)和对药物的担忧(p<0.01));(3)医生评估的患者依从性(p<0.01);(4)MMAS - 4(p<0.01)以及(5)TBQ(p<0.01)之间存在线性关系。重测的可靠性良好(ICC为0.67,95%置信区间为0.42至0.85)。
我们开发了一种具有可接受的效度和信度的工具,用于评估患者所服用的每种药物的依从性,可用于医院和初级保健机构。